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Parvalbumin neurons as a hub in autism
spectrum disorders
Autism spectrum disorder (ASD) is a heterogeneous and complex group
of neurodevelopmental disorders characterized by impairments in
social behavior and language/communication and the presence of
repetitive or stereotyped patterns of behaviors. Up to 1 in 70 children
(with a 4:1 preference in boys) is diagnosed with ASD before the age
of three, however no effective treatment directed at the core symp-
toms of ASD is available on the market. A major challenge in ASD
research remains the elucidation of the disease etiology. It is widely
accepted that a combination of genetic, epigenetic, and environmental
risk factors contribute to the development of ASD, yet with several
hundreds (!) of risk genes, no consistent theory concerning ASD patho-
physiology has been established (de la Torre-Ubieta, Won, Stein, &
Geschwind, 2016). It is assumed that these risk factors cause (directly
or indirectly) impairments in synaptic transmission, resulting in region-
specific and occasionally temporally restricted imbalances between
excitation and inhibition in the brain, ultimately leading to behavioral
and cognitive deficits. Recently, an unconventional but interesting
hypothesis was put forward, suggesting that ASD is not a disorder, but
rather the end result of functional adaptive/homeostatic mechanisms
during neurodevelopment under pre-stressed conditions. According to
this hypothesis, ASD is not even a disease, adding another dimension
on explanative theories on ASD etiology.
In order to facilitate treatment approaches, identification of conver-
gent pathways, or common endpoints, during ASD development are
highly needed. In our research projects, the focus is centered on a protein
called parvalbumin (PV). PV is a calcium-binding protein expressed in a
subset of GABAergic interneurons in the brain. Several studies have
shown that signaling is impaired in PV-expressing interneurons (hereafter
termed Pvalb neurons) and/or that their numbers are decreased in human
ASD patients and different ASD mouse models (Hashemi, Ariza, Rogers,
Noctor, & Martínez-Cerde~no; W€ohr et al., 2015). Moreover, knockout
mice for PV (PV2/2) show a strong ASD-associated phenotype at the
juvenile stage (1 month of age). Of note, the human PVALB gene is not
found on the list of ASD-risk genes, indicating that disrupting the proper
functioning of Pvalb neuron-containing neuronal networks by PV-
downregulation is sufficient to induce an ASDphenotype inmice without
another predisposition (W€ohr et al., 2015). In the last few years, we have
tested different and well-established mouse models of ASD with a focus
on Pvalb neurons. Unlike many other groups, we use two different
markers to identify and quantify the number of Pvalb neurons: first, with
an antibody against PV and second, biotinylated Vicia Villosa Agglutinin
(VVA) to label perineuronal nets (PNN), which consist of extracellular
matrix components and preferentially surround Pvalb neurons, thus rep-
resenting a second independent marker for identifying Pvalb neurons
(Figure 1). Using this approach, we have shown that in postnatal day
(PND) 25 PV2/2 mice, Pvalb neurons are not absent—as could be
deduced by the complete absence of PV immunoreactivity—but deficient
of PV. Similar observations were made in PV1/2, Shank12/2,
Shank3B2/2 (Filice, V€orckel, Sungur, W€ohr, & Schwaller, 2016), and in
utero valproic acid (VPA)-exposedmice (Lauber, Filice, & Schwaller, 2016).
In all of these models, we observe lower numbers of PV-immunoreactive
cells and decreased PV protein (and PvalbmRNA) levels compared toWT
mice; however the number of VVA-positive PNN-ensheathed cells is
unchanged, indicating that PV protein expression is strongly down-
regulated in Pvalb neurons of these genetic and environmental ASD
mouse models (Figure 1). In support, RNA-seq and qRT-PCR analyses of
post-mortem samples of frontal cortex, temporal cortex, and cerebellum
from ASD individuals, compared to control individuals, revealed that the
most significant changes include a decrease in PVALBmRNA levels (Parik-
shak et al., 2016). Accordingly, we hypothesize that Pvalb neurons
undergo adaptive/homeostatic changes during early postnatal develop-
ment, under pre-stressed conditions, such as the ones caused by muta-
tions in proteins associated with synapses (e.g., SHANK proteins), or
when challenged prenatally by environmental insults, as observed in the
VPAmodel. Down-regulation of PV levels might enable a Pvalb neuron to
modulate its own output and subsequently keep the excitation/inhibition
balance of brain circuits within a proper “physiological” window during
the maturation period of Pvalb neurons (i.e., mostly during the first post-
natal month in mice). In this context, the ASD phenotype emerging in the
PV2/2 and other ASDmousemodels with confirmed PV deficits may be
viewed as the consequence or “cost” of such a correction.
Interestingly, in the VPA mouse model, PV down-regulation is
restricted to the striatum, whereas no changes are found in the investi-
gated cortical regions (medial prefrontal cortex, somatosensory cortex).
However, in the cortex of PND25 VPA-exposed mice, we detect
decreased levels of Kv3.1, a voltage-dependent potassium channel that
is exclusively expressed on the surface of Pvalb neurons. Blocking
Kv3.1 conductances or knocking out Kcnc1, the gene coding for Kv3.1,
leads to a broadening of AP duration due to a reduced rate of repolari-
zation (Espinosa, Torres-Vega, Marks, & Joho, 2008). As a result, neuro-
transmitter release from these neurons is increased, presumably
enhancing Pvalb neuron-mediated inhibition. A similar effect is
observed in PV-deficient Pvalb neurons, since the absence of PV
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frequency-dependent output from Pvalb neurons (Schwaller, 2012).
These observations indicate that the output of Pvalb neurons may be
modulated by different means in a circuit-specific manner. Hence, re-
establishing PV levels or modulating Pvalb cell neuronal output during
critical periods of neurodevelopment (e.g., during the early postnatal
period coinciding with PV upregulation and maturation of the Pvalb
neuron network) might reduce or even abolish the core symptoms of
ASD. Experiments aimed at answering these questions are currently
underway in our lab. From a clinical point of view, this strategy repre-
sents a new and putatively promising approach for the treatment of
ASD individuals with different predispositions.
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FIGURE 1 Section from the striatum of a VPAmouse. Pvalb neurons are visualized by VVA-positive PNN (green) and by antibodies against PV (red).
The two cells on the right side (indicated by arrowheads) are presumably Pvalb neurons with low-to-absent PV levels. In the third panel, green and red
images aremerged and additionally cell nuclei are visualized byDAPI staining (blue). Scale bar: 50 lm
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